Keros Therapeutics director buys 1,000 shares

Keros Therapeutics director Jean Jacques Bienaime purchased 1,000 shares of Common Stock on July 15, 2026 at a weighted-average price of $10.61 per share, with individual trades between $10.46 and $10.80.

Rhea-AI Filing Summary

Keros Therapeutics director Jean Jacques Bienaime purchased 1,000 shares of Common Stock on July 15, 2026 at a weighted-average price of $10.61 per share, with individual trades between $10.46 and $10.80. The purchase was made under a Rule 10b5-1 trading plan adopted on December 5, 2025, increasing his direct holdings to 18,592 shares.

Insider Trade Summary 10b5-1

Net Buyer: 1,000 shares

Net Buy 1 txn

Insider BIENAIME JEAN JACQUES

Role Director

Bought 1,000 shs ($11K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1, F2	1,000	$10.61	$11K

Holdings After Transaction: Common Stock — 18,592 shares (Direct)

Footnotes (2)

1. F1. Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
2. F2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.46 to $10.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Key Figures

Shares purchased: 1,000 shares Weighted-average purchase price: $10.61 per share Trade price range: $10.46–$10.80 per share +3 more

6 metrics

Shares purchased 1,000 shares Non-derivative Common Stock purchase on 2026-07-15

Weighted-average purchase price $10.61 per share Average price for the 1,000-share buy on 2026-07-15

Trade price range $10.46–$10.80 per share Range of individual purchase prices within the reported transaction

Shares owned after transaction 18,592 shares Direct Common Stock holdings following the 1,000-share purchase

Transaction date 2026-07-15 Date of the reported Common Stock purchase

10b5-1 plan adoption date December 5, 2025 Date the Rule 10b5-1 trading plan governing this purchase was adopted

Key Terms

Rule 10b5-1 trading plan, weighted average price, Reporting Person

3 terms

Rule 10b5-1 trading plan financial

"Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Reporting Person financial

"The Reporting Person undertakes to provide to the Issuer any security holder"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider share purchase did Keros Therapeutics (KROS) disclose?

Keros Therapeutics reported a director purchase of 1,000 Common Stock shares. On July 15, 2026, director Jean Jacques Bienaime bought 1,000 shares at a weighted-average price of $10.61 per share, increasing his directly held position to a total of 18,592 shares.

At what price were the Keros Therapeutics (KROS) shares bought by Jean Jacques Bienaime?

The weighted-average purchase price was $10.61 per share. According to the disclosure, the 1,000 shares were acquired in multiple transactions, with individual trade prices ranging from $10.46 to $10.80 per share, all reported as a single weighted-average figure.

How many Keros Therapeutics (KROS) shares does Jean Jacques Bienaime own after this transaction?

After the reported purchase, Jean Jacques Bienaime directly owns 18,592 shares. The Form 4 shows that his total direct holdings in Keros Therapeutics Common Stock increased from prior levels to 18,592 shares following the 1,000-share acquisition on July 15, 2026.

Was the Keros Therapeutics (KROS) insider trade made under a Rule 10b5-1 plan?

Yes, the transaction was executed under a Rule 10b5-1 trading plan. The footnotes state that the shares were purchased pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 5, 2025, indicating a pre-arranged trading framework for these purchases.

Is Jean Jacques Bienaime’s Keros Therapeutics (KROS) position direct or indirect?

The reported 18,592-share position is held directly. The ownership code for this Common Stock holding is listed as “D,” indicating direct ownership by the reporting person rather than through a trust, entity, or other indirect ownership structure.

How many Keros Therapeutics (KROS) insider buy transactions are included in this Form 4?

The filing reflects a single reported purchase transaction totaling 1,000 shares. The transaction summary shows one buy transaction and no sales, gifts, or derivative exercises, resulting in a net purchase of 1,000 Keros Therapeutics Common Stock shares by the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 04:10 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BIENAIME JEAN JACQUES

(Last) (First) (Middle)

C/O KEROS THERAPEUTICS, INC.

1050 WALTHAM STREET, SUITE 302

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Keros Therapeutics, Inc. [ KROS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		P(1)		1,000	A	$10.61(2)	18,592	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.46 to $10.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ Esther Cho, Attorney-in-Fact	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)